Twist Bioscience Corp
TWST35.320USD
+0.580+1.67%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.14BMarket Cap
LossP/E TTM
More Details of Twist Bioscience Corp Company
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Twist Bioscience Corp Info
Ticker SymbolTWST
Company nameTwist Bioscience Corp
IPO dateOct 31, 2018
CEOLeproust (Emily M)
Number of employees979
Security typeOrdinary Share
Fiscal year-endOct 31
Address681 Gateway Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone18007190671
Websitehttps://www.twistbioscience.com/
Ticker SymbolTWST
IPO dateOct 31, 2018
CEOLeproust (Emily M)
Company Executives of Twist Bioscience Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
419.69K
-154368.00%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
123.75K
-85020.00%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
94.05K
+1343.00%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
70.48K
-16772.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
61.82K
-29002.00%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
37.56K
-9632.00%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
23.68K
+1436.00%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
17.16K
+1344.00%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
10.39K
+4834.00%
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
419.69K
-154368.00%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
123.75K
-85020.00%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
94.05K
+1343.00%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
70.48K
-16772.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
61.82K
-29002.00%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
37.56K
-9632.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
NGS tools
208.10M
55.26%
Synthetic genes
113.60M
30.17%
Antibody discovery
23.45M
6.23%
Oligo pools
20.23M
5.37%
DNA libraries
11.18M
2.97%
By RegionUSD
Name
Revenue
Proportion
Americas
225.58M
59.90%
EMEA
124.24M
32.99%
APAC
26.75M
7.10%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
NGS tools
208.10M
55.26%
Synthetic genes
113.60M
30.17%
Antibody discovery
23.45M
6.23%
Oligo pools
20.23M
5.37%
DNA libraries
11.18M
2.97%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.98%
Artisan Partners Limited Partnership
10.46%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
7.85%
William Blair Investment Management, LLC
6.76%
Other
54.55%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.98%
Artisan Partners Limited Partnership
10.46%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
7.85%
William Blair Investment Management, LLC
6.76%
Other
54.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
66.13%
Investment Advisor/Hedge Fund
36.09%
Hedge Fund
9.93%
Research Firm
5.45%
Individual Investor
2.69%
Pension Fund
1.58%
Bank and Trust
0.55%
Family Office
0.17%
Insurance Company
0.07%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
570
73.25M
119.55%
-1.03M
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
6.73M
10.98%
+326.37K
+5.10%
Sep 30, 2025
Artisan Partners Limited Partnership
6.41M
10.46%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.76M
9.39%
-63.16K
-1.09%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.81M
7.85%
-46.27K
-0.95%
Sep 30, 2025
William Blair Investment Management, LLC
4.14M
6.76%
+235.68K
+6.03%
Sep 30, 2025
EdgePoint Investment Group Inc.
4.08M
6.66%
+1.70M
+71.10%
Sep 30, 2025
State Street Investment Management (US)
3.09M
5.04%
+588.07K
+23.51%
Sep 30, 2025
Amova Asset Management Co., Ltd.
2.12M
3.46%
-179.23K
-7.79%
Sep 30, 2025
Soleus Capital Management, L.P.
1.87M
3.05%
+1.51M
+426.59%
Sep 30, 2025
Millennium Management LLC
1.79M
2.93%
+1.08M
+151.55%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
View more
ARK Genomic Revolution ETF
Proportion6.24%
iShares Genomics Immunology and Healthcare ETF
Proportion3.92%
Global X Genomics & Biotechnology ETF
Proportion2.09%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2%
WisdomTree BioRevolution Fund
Proportion1.79%
ARK Innovation ETF
Proportion1.47%
Franklin Genomic Advancements ETF
Proportion1.17%
State Street SPDR S&P Biotech ETF
Proportion0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.66%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.56%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Twist Bioscience Corp?
The top five shareholders of Twist Bioscience Corp are:
ARK Investment Management LLC holds 6.73M shares, accounting for 10.98% of the total shares.
Artisan Partners Limited Partnership holds 6.41M shares, accounting for 10.46% of the total shares.
The Vanguard Group, Inc. holds 5.76M shares, accounting for 9.39% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.81M shares, accounting for 7.85% of the total shares.
William Blair Investment Management, LLC holds 4.14M shares, accounting for 6.76% of the total shares.
ARK Investment Management LLC holds 6.73M shares, accounting for 10.98% of the total shares.
Artisan Partners Limited Partnership holds 6.41M shares, accounting for 10.46% of the total shares.
The Vanguard Group, Inc. holds 5.76M shares, accounting for 9.39% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.81M shares, accounting for 7.85% of the total shares.
William Blair Investment Management, LLC holds 4.14M shares, accounting for 6.76% of the total shares.
What are the top three shareholder types of Twist Bioscience Corp?
The top three shareholder types of Twist Bioscience Corp are:
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.
How many institutions hold shares of Twist Bioscience Corp (TWST)?
As of 2025Q4, 570 institutions hold shares of Twist Bioscience Corp, with a combined market value of approximately 73.25M, accounting for 119.55% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.46%.
What is the biggest source of revenue for Twist Bioscience Corp?
In FY2025, the NGS tools business generated the highest revenue for Twist Bioscience Corp, amounting to 208.10M and accounting for 55.26% of total revenue.
